Lp(a) Q&A: Testing Kids, The Saturated Fat Debate, and Aspirin Risks
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
Lp(a) Q&A: Testing Kids, The Saturated Fat Debate, and Aspirin Risks
-
Letto da:
-
Di:
Following our deep dive into Lipoprotein(a), Dr. Ravi Kumar answers the most pressing listener questions to help you navigate the complexities of this genetic heart risk.
In this Q&A session, we move beyond the basics to address real-world clinical concerns and the future of cardiovascular medicine.
We discuss:
- Testing the Next Generation: Why Lp(a) is essentially stable from age 5 and why testing your children can provide a 40-year head start on prevention.
- The Saturated Fat Paradox: Analyzing the Delta trials and why replacing saturated fats with carbohydrates might actually increase your Lp(a) levels.
- Exercise & The "Table" Analogy: Why exercise doesn't change the cards you’re dealt (your Lp(a) number), but fundamentally changes the "table" you're playing on.
- The Aspirin Protocol: A look at the Women's Health Study and why low-dose aspirin may specifically benefit those with the high-risk LPA gene variant.
- SiRNA Breakthroughs: An update on Pelacarsen and Olpasiran—drugs that can slash Lp(a) by 90%—and whether you should wait for them to hit the market.
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione